Detalhe da pesquisa
1.
Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (177 Lu-J591) for Metastatic Castration-Resistant Prostate Cancer.
Oncologist
; 25(6): 477-e895, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31999003
2.
Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177 Lu-J591) for metastatic castration-resistant prostate cancer.
Cancer
; 125(15): 2561-2569, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31012963
3.
Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer.
Urol Oncol
; 38(11): 848.e9-848.e16, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32600929
4.
Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation.
Mol Cancer Ther
; 17(9): 1927-1940, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29891487
5.
Induction of PSMA and Internalization of an Anti-PSMA mAb in the Vascular Compartment.
Mol Cancer Res
; 14(11): 1045-1053, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27458033
6.
Can the interplay between androgen signaling and PSMA expression be leveraged for theranostic applications?
Transl Androl Urol
; 8(Suppl 3): S263-S264, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-31392140